An observational study in Malignant Distal Biliary Obstruction, sponsored by Shengjing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Shengjing Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this multicenter observational study is to compare the clinical efficacy and safety of 8-mm versus 10-mm percutaneously placed uncovered self-expandable metal stents in patients with malignant distal biliary obstruction .
Malignant obstructive jaundice (MOJ) is a clinical syndrome characterized by impaired bile drainage and elevated serum bilirubin levels resulting from direct invasion, compression, or metastatic involvement of the extrahepatic biliary tract by malignant tumors. Malignant distal biliary obstruction (MDBO) is an important cause of MOJ, commonly arising from pancreatic head cancer, ampullary carcinoma, distal cholangiocarcinoma, gallbladder cancer, or metastatic malignancies involving the distal biliary tract. For patients who are not candidates for curative surgical resection or require biliary decompression before anticancer treatment, biliary drainage and stent placement are important therapeutic approaches to relieve jaundice, improve liver function, alleviate symptoms, and enhance quality of life.
Percutaneous transhepatic biliary drainage (PTBD) and percutaneous transhepatic metallic biliary stent placement are important interventional radiological approaches for the management of MDBO. Compared with long-term external biliary drainage, metallic stent placement restores internal bile drainage and reduces the adverse effects of external drainage on digestion, nutrient absorption, quality of life, and daily catheter care. Self-expandable metal stents (SEMSs), which are widely used in the palliative management of malignant biliary obstruction, offer several advantages, including a minimally invasive approach, strong radial force, and favorable biliary patency. Nevertheless, complications following metallic stent placement remain a concern, including nonocclusion cholangitis(NOC) , recurrent biliary obstruction (RBO), stent occlusion, stent migration, bacterial adhesion, and biofilm formation. The diagnosis of cholangitis can be guided by the Tokyo Guidelines 2018 (TG18), whereas RBO can be assessed according to established definitions of biliary stent dysfunction and the relevant Tokyo criteria.
Both 8-mm and 10-mm diameter metallic stents are commonly used in the clinical management of MDBO. Theoretically, the larger lumen of a 10-mm stent may provide more effective initial biliary drainage and greater resistance to occlusion. However, a larger stent diameter may also increase irritation of the bile duct wall, duodenobiliary reflux, and the risk of ascending bacterial colonization. Conversely, an 8-mm stent may offer potential advantages by reducing excessive biliary dilation, reflux, and irritation of the bile duct wall, although its smaller lumen may increase the risk of stent occlusion. In recent years, several studies have compared the clinical performance of self-expandable metal stents with different diameters in patients with MDBO, including comparisons between 6-mm and 10-mm stents and between 10-mm and 12-mm stents. However, evidence regarding the comparative outcomes of 8-mm and 10-mm stents placed via a percutaneous approach remains limited, particularly with respect to long-term stent patency, cholangitis risk, and overall survival. Further accumulation and validation of real-world clinical evidence are therefore warranted.
The present study aims to retrospectively collect clinical data from patients with MDBO in a real-world setting and compare the clinical outcomes of 8-mm and 10-mm metallic biliary stents in terms of postprocedural cholangitis, RBO, stent patency duration, overall survival, and safety.
Shengjing Hospital is the lead sponsor of 129 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with malignant distal biliary obstruction (MDBO) who underwent treatment at multiple centers between January 2020 and January 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Age ≥18 years.; 2) clinically or histopathologically confirmed MDBO (≤2 cm distal to the biliary hilum); 3) with symptoms related to MBO (jaundice, pruritus, cholangitis, or pain); 4) unresectability because of extensive lesions, , poor medical condition, or refusal to be surgically treated; 5) ith clear consciousness, cooperation, and an (ECOG) performance status of 0, 1, 2 or 3.
Exclusion Criteria:
1) benign biliary obstruction; 2) performance status of 4; 3) a history of biliary stenting or bile tract surgery; 4) intestinal obstruction distal to the ampulla; 5) pregnancy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stent Diameter
Stent Diameter
Incidence of Nonocclusion Cholangitis
Time from biliary stent placement to the first occurrence of nonocclusion cholangitis
Time frame: Typically within 1 year.
Stent Patency Duration
Time from biliary stent placement to the occurrence of recurrent biliary obstruction.
Time frame: Typically within 1 year.
Overall Survival
Time from biliary stent placement to death from any cause.
Time frame: Typically within 3 months to 2 years.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.